Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.

Overview
Research
Identity
Additional Document Info
View All

authors

Barthélemy, Nicolas R
Bateman, Randall J
Hirtz, Christophe
Marin, Philippe
Becher, François
Sato, Chihiro
Gabelle, Audrey
Lehmann, Sylvain

publication date

January 1, 2020

published in

Alzheimer's research & therapy Journal

has subject area